Progression of renal failure -- the role of hypertension

• Published in: Annals of the Academy of Medicine, Singapore Vol. 34; no. 1; pp. 8 - 15
• Main Author: Whitworth, J A
• Format: Journal Article
• Language: English
• Published: Singapore 01.01.2005
• Subjects: Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Animals; Blood Pressure - drug effects; Blood Pressure - physiology; Calcium Channel Blockers - therapeutic use; Disease Progression; Humans; Hypertension, Renovascular - complications; Hypertension, Renovascular - drug therapy; Hypertension, Renovascular - physiopathology; Renal Insufficiency - etiology; Renal Insufficiency - physiopathology; Renal Insufficiency - prevention & control
• ISSN: 0304-4602; 0304-4602
• DOI: 10.47102/annals-acadmedsg.V34N1p8

High blood pressure plays a key role in the progression of renal failure. Hypertension is a common presentation of kidney disease and an almost invariable accompaniment of renal failure. Hypertension is also a major contributor to cardiovascular disease, the major cause of morbidity and mortality in renal failure. Hypertension is both cause and consequence of renal failure, but the precise nature and prevalence of hypertensive nephrosclerosis as a cause of renal failure remains controversial. There is strong evidence that hypertension accelerates the progression of experimental renal disease and that control of blood pressure is effective in preventing this progression. Hypertension, both accelerated and "benign" (a misnomer), has long been recognised as a poor prognostic feature in human renal disease and more recently in renal allograft survival. Blood pressure control is very effective in retarding renal disease progression. There are compelling indications for angiotensin-converting enzyme inhibitors in both non-diabetic and type 1 diabetic nephropathies, and for angiotensin receptor blockers in type 2 diabetic nephropathy. Most patients will require combination drug therapy to control blood pressure and reduce both progression of renal failure and the associated cardiovascular morbidity and mortality.